+

PE20030333A1 - Compuestos biciclicos aromaticos sustituidos con amino-alquilo, procedimiento para su preparacion y su utilizacion como medicamentos - Google Patents

Compuestos biciclicos aromaticos sustituidos con amino-alquilo, procedimiento para su preparacion y su utilizacion como medicamentos

Info

Publication number
PE20030333A1
PE20030333A1 PE2002000743A PE2002000743A PE20030333A1 PE 20030333 A1 PE20030333 A1 PE 20030333A1 PE 2002000743 A PE2002000743 A PE 2002000743A PE 2002000743 A PE2002000743 A PE 2002000743A PE 20030333 A1 PE20030333 A1 PE 20030333A1
Authority
PE
Peru
Prior art keywords
alkyl
aryl
amino
medicines
procedure
Prior art date
Application number
PE2002000743A
Other languages
English (en)
Inventor
Matthias Gossel
Siegfried Stengelin
Lothar Schwink
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of PE20030333A1 publication Critical patent/PE20030333A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS BICICLICOS AROMATICOS SUSTITUIDOS CON AMINO ALQUILO DE FORMULA I, A ES ALQUILO C1-C8, ALQUILEN C0-C8-ARILO, ANILLO MONOCICLICO, BICICLICO DE 3-12 MIEMBROS, O-ALQUILO C1-C6, S-ALQUILO C1-C6, NHCO-ALQUILO C1-C6; X ES ENLACE, C(R8)(R9), C(OR10)(R11), O, NR12, S, SO, SO2, CO; X ES C(R8)(R9), C(OR10)(R11), O, NR12, S, SO, SO2, CO; R8, R9, R10, R11, R12 SON H, ALQUILO C1-C6; D ES N, CR41; E ES N, CR42, G ES N, CR43; L ES N, CR44; R1, R2, R3, R41, R43, R44 SON H, F, Br, I, OH, CF3, NO2, CN, OCF3, O-ALQUILO C1-C6, ALCOXI-ALQUILO C1-C4, ENTRE OTROS; R13, R14, R15, R16, R17, R19, R24, R5 SON H, ALQUILO C1-C6 O R13 Y R14 O R15 Y R16 JUNTO A N FORMAN UN ANILLO DE 5-6 MIEMBROS, ENTRE OTROS; R18, R20, R21 SON ALQUILO C1-C6, ARILO; B ES NR24, O; W ES N, CR25; R25 ES H, ALQUILO C1-C6, ARILO, UN ENLACE CON Y; T ES N, CR26; R26 ES H, ALQUILO C1-C6, ARILO, ALQUILEN C0-C8-ARILO, U ES O, S, NR27, C(R30)=N, N=CR31; R27, R30, R31 SON H, ALQUILO C1-C6, UN ENLACE CON Y; Y ES ALQUILENO C1-C8; R6 Y R7 SON H, ALQUILO C1-C6, CICLOALQUILO C3-C7 O R6 E Y O R6 Y R7 FORMAN JUNTO A N UN ANILLO DE 3-8 MIEMBROS. SON COMPUESTOS PREFERIDOS 1-[1-(2-DIMETILAMINO-ETIL)-1H-INDOL-5-IL]-3-(4-FENOXI-FENIL)-UREA; 1-(4-BUTOXI-FENIL)-3-[1-(2-DIMETILAMINO-ETIL)-1H-INDOL-5-IL]-UREA; 1-(1-METIL-2-PIRROLIDIN-1-IL-METIL)-1H-INDOL-5-IL)-3-(4-FENOXI-FENIL)-UREA, ENTRE OTROS. LOS COMPUESTOS SON ANOREXICOS, TIENEN EFECTO SOBRE EL METABOLISMO Y PUEDEN SER UTILES PARA TRATAMIENTO DE OBESIDAD, DIABETES
PE2002000743A 2001-08-17 2002-08-16 Compuestos biciclicos aromaticos sustituidos con amino-alquilo, procedimiento para su preparacion y su utilizacion como medicamentos PE20030333A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10139416A DE10139416A1 (de) 2001-08-17 2001-08-17 Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
PE20030333A1 true PE20030333A1 (es) 2003-04-24

Family

ID=7695086

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000743A PE20030333A1 (es) 2001-08-17 2002-08-16 Compuestos biciclicos aromaticos sustituidos con amino-alquilo, procedimiento para su preparacion y su utilizacion como medicamentos

Country Status (23)

Country Link
US (5) US20030212070A1 (es)
EP (1) EP1418906A1 (es)
JP (1) JP2005505530A (es)
KR (1) KR20040043197A (es)
CN (1) CN1555260A (es)
AR (1) AR043477A1 (es)
BR (1) BR0211989A (es)
CA (1) CA2457037A1 (es)
DE (1) DE10139416A1 (es)
EE (1) EE200400055A (es)
GT (1) GT200200165A (es)
HR (1) HRP20040149A2 (es)
HU (1) HUP0401329A2 (es)
IL (1) IL160424A0 (es)
MX (1) MXPA04001307A (es)
NO (1) NO20040678L (es)
PA (1) PA8553001A1 (es)
PE (1) PE20030333A1 (es)
PL (1) PL366794A1 (es)
RU (1) RU2004107654A (es)
UY (1) UY27417A1 (es)
WO (1) WO2003015769A1 (es)
ZA (1) ZA200401221B (es)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0700124A2 (en) 2001-10-25 2007-06-28 Takeda Chemical Industries Ltd Quinoline compound
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
US7541477B2 (en) 2002-07-30 2009-06-02 Banyu Pharmaceutical Co., Ltd. Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
WO2004034968A2 (en) * 2002-08-20 2004-04-29 The Regents Of The University Of California Combination therapy for controlling appetites
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004209505B2 (en) * 2003-02-10 2009-07-23 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
DE10314610A1 (de) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
AU2004266228A1 (en) * 2003-08-13 2005-03-03 Amgen, Inc. Melanin concentrating hormone receptor antagonists
MXPA06001636A (es) 2003-08-13 2006-04-28 Amgen Inc Antagonista del receptor de la hormona concentradora de melanina.
US7504412B2 (en) 2003-08-15 2009-03-17 Banyu Pharmaceuticals, Co., Ltd. Imidazopyridine derivatives
FR2859472A1 (fr) * 2003-09-04 2005-03-11 Oreal Utilisation, pour la teinture des fibres keratiniques, d'un derive de para-phenylenediamine substituee par un noyau homopiperidine
CA2540845C (en) * 2003-10-02 2010-11-09 Schering Corporation Aminobenzimidazoles as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
WO2005035534A1 (ja) * 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
SE0303480D0 (sv) * 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
US7049307B2 (en) 2003-12-23 2006-05-23 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
US7071182B2 (en) 2003-12-23 2006-07-04 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
FR2864957A1 (fr) * 2004-01-09 2005-07-15 Oreal Composition pour la teinture des fibres keratiniques comprenant au moins un derive de para-phenylenediamine substitue par un noyau heptamethylenediamine
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
DE102004017932A1 (de) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
WO2005123714A1 (en) * 2004-06-16 2005-12-29 7Tm Pharma A/S Quinazoline compounds and their use in mch-related disease
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1632491A1 (en) 2004-08-30 2006-03-08 Laboratorios Del Dr. Esteve, S.A. Substituted indole compounds and their use as 5-HT6 receptor modulators
WO2006062984A2 (en) * 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
JP2008523071A (ja) * 2004-12-07 2008-07-03 ルーカス ファーマシューティカルズ， インコーポレイテッド Ｍａｐキナーゼの尿素インヒビター
ATE404555T1 (de) * 2004-12-17 2008-08-15 Lilly Co Eli Neue mch-rezeptorantagonisten
CN102267978A (zh) * 2005-01-14 2011-12-07 Cgi药学股份有限公司 作为激酶活性调节剂的1,3-二芳基取代的脲
WO2007024294A2 (en) * 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
TW200722084A (en) * 2005-05-18 2007-06-16 Neuraxon Inc Substituted benzimidazole compounds with dual NOS inhibitory activity and μ opioid agonist activity
US20070185098A1 (en) * 2006-01-04 2007-08-09 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
MX2009001043A (es) 2006-08-08 2009-02-06 Sanofi Aventis Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso.
EP2076261A2 (en) * 2006-10-03 2009-07-08 Ranbaxy Laboratories, Ltd. Muscarinic receptor antagonists
AU2007328979B2 (en) * 2006-12-05 2013-05-09 Janssen Pharmaceutica N.V. Novel substituted diaza spiro pyridinone derivatives for use in MCH-1 mediated diseases
US8198307B2 (en) * 2007-05-11 2012-06-12 Korea Research Institute Of Chemical Technology Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same
ES2559319T3 (es) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
IE20070928A1 (en) * 2007-12-21 2009-09-30 Giuliani Int Ltd Multi target ligands
JPWO2009123194A1 (ja) * 2008-04-01 2011-07-28 武田薬品工業株式会社 複素環化合物
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
EP2486029B1 (en) 2009-09-30 2015-06-10 Boehringer Ingelheim International GmbH Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
WO2011083804A1 (ja) * 2010-01-06 2011-07-14 武田薬品工業株式会社 インドール誘導体
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8697739B2 (en) * 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
RS55662B1 (sr) 2010-10-06 2017-06-30 Glaxosmithkline Llc Derivati benzimidazola kao inhibitori pi3 kinaze
BR122021002201A8 (pt) 2011-02-25 2023-04-11 Merck Sharp & Dohme Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
EP3366698A1 (en) 2011-03-01 2018-08-29 Synergy Pharmaceuticals Inc. Guanylate cyclase c agonists
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8795850B2 (en) * 2011-05-19 2014-08-05 Universal Display Corporation Phosphorescent heteroleptic phenylbenzimidazole dopants and new synthetic methodology
US9192617B2 (en) * 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP2880028B1 (en) 2012-08-02 2020-09-30 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX2015010935A (es) 2013-02-22 2015-10-29 Merck Sharp & Dohme Compuestos biciclicos antidiabeticos.
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
PT2981271T (pt) 2013-04-05 2019-02-19 Boehringer Ingelheim Int Utilizações terapêuticas de empagliflozina
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EA033286B1 (ru) 2013-04-18 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Способ лечения или отсрочки развития хронической болезни почек
HRP20240805T1 (hr) 2013-06-05 2024-09-27 Bausch Health Ireland Limited Ultra-pročišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i uporabe
CA2925862A1 (en) * 2013-10-01 2015-04-09 Glaxosmithkline Intellectual Property Development Limited Compounds for affinity chromatography and for extending the half-life of a therapeutic agent
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN103864753B (zh) * 2014-02-27 2016-01-20 华东师范大学 含有五元芳杂环结构的抗丙肝化合物及制备方法和用途
BR112017000714A2 (pt) * 2014-07-16 2018-01-09 Novogen ltd indols funcionalizados e substituídos como agentes anti-câncer
WO2016077704A1 (en) * 2014-11-14 2016-05-19 The Regents Of The University Of California Modulation of agpat5 expression
EP3538107A1 (en) 2016-11-10 2019-09-18 Boehringer Ingelheim International GmbH Pharmaceutical composition, methods for treating and uses thereof
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
MA44795B1 (fr) 2017-03-20 2019-09-30 Forma Therapeutics Inc Compositions de pyrrolopyrrole en tant qu'activateurs de la pyruvate kinase (pkr)
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
CN113226356B (zh) 2018-09-19 2025-03-04 诺沃挪第克健康护理股份公司 活化丙酮酸激酶r
BR112022004376A2 (pt) 2019-09-19 2022-06-07 Forma Therapeutics Inc Ativação de piruvato quinase r
EP4245749A4 (en) * 2020-11-13 2024-11-20 Institute for Basic Science NOVEL AMINOAROMATIC COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES COMPRISING IT AS ACTIVE INGREDIENT
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2928485A1 (de) * 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
US5599930A (en) * 1991-07-03 1997-02-04 The Upjohn Company Substituted indoles as anti-AIDS pharmaceuticals
US5756496A (en) * 1994-05-28 1998-05-26 Smithkline Beecham P.L.C. Amide derivatives having 5HT1D-antagonist activity
AU708055B2 (en) * 1996-02-02 1999-07-29 Merck & Co., Inc. Heterocyclic derivatives as antidiabetic and antiobesity agents
DE69839305T2 (de) * 1997-02-27 2009-04-09 Takeda Pharmaceutical Co. Ltd. Aminderivate, ihre herstellung und verwendung als inhibitoren der produktion von amyloid-beta
WO1998047868A1 (en) * 1997-04-18 1998-10-29 Smithkline Beecham Plc Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists
CA2313125A1 (en) * 1997-12-12 1999-06-24 Laramie Mary Gaster Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
EP1218336A2 (en) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
BR0111457A (pt) * 2000-06-09 2003-06-24 Aventis Pharma Deustschland Gm Derivados de acilfeniluréia, processos para a sua preparação e sua aplicação como medicamentos
FR2810979B1 (fr) * 2000-06-29 2002-08-23 Adir Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
GT200200165A (es) 2003-05-22
PL366794A1 (en) 2005-02-07
EP1418906A1 (de) 2004-05-19
HRP20040149A2 (en) 2004-08-31
KR20040043197A (ko) 2004-05-22
IL160424A0 (en) 2004-07-25
RU2004107654A (ru) 2005-09-10
US20040198731A1 (en) 2004-10-07
US20040198733A1 (en) 2004-10-07
UY27417A1 (es) 2002-11-29
PA8553001A1 (es) 2003-02-28
AR043477A1 (es) 2005-08-03
WO2003015769A1 (de) 2003-02-27
BR0211989A (pt) 2004-09-28
EE200400055A (et) 2004-04-15
CA2457037A1 (en) 2003-02-27
US20040198732A1 (en) 2004-10-07
CN1555260A (zh) 2004-12-15
DE10139416A1 (de) 2003-03-06
US20040192693A1 (en) 2004-09-30
JP2005505530A (ja) 2005-02-24
NO20040678L (no) 2004-05-13
ZA200401221B (en) 2004-10-27
MXPA04001307A (es) 2004-05-20
US20030212070A1 (en) 2003-11-13
HUP0401329A2 (hu) 2004-12-28

Similar Documents

Publication Publication Date Title
PE20030333A1 (es) Compuestos biciclicos aromaticos sustituidos con amino-alquilo, procedimiento para su preparacion y su utilizacion como medicamentos
PE20081493A1 (es) Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos y su uso
TW368500B (en) 1-Benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one derivatives
KR940005633A (ko) 약제학적으로 유용한 항경련제 설파메이트의 이미데이트 유도체
AR016817A1 (es) Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
ES2150577T3 (es) Aminoeteres aromaticos como agentes para aliviar el dolor.
EE200300228A (et) Tiotroopium- ja salmeteroolsooladel põhinevad ravimkompositsioonid
PE20040960A1 (es) Derivados de piperazina acilados como agonistas del receptor de melanocortina-4
GT200300075A (es) Compuestos que modulan la actividad ppar y procedimientos para su preparacion
CY1110651T1 (el) Παραγωγα της ν-'(1,5-διφαινυλ-1η- πυραζολ-3-υλ)μεθυλ σουλφοναμιδης με μια συγγενεια για τους υποδοχεις cb1
ECSP024364A (es) Antagonistas receptores de adenosina a2a
PE20060500A1 (es) Derivados de heteroaril sulfamida benzo-fusionada como anticonvulsivantes
EA200200571A1 (ru) Новая композиция и ее применение
AR054799A1 (es) Derivados de oxindol
PE20040909A1 (es) Derivados fluoroglicosidos aromaticos con afinidad por el receptor sglt2
PE20081557A1 (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
CR9078A (es) Derivado de bencimidazol ariloxi-sustituidos
ES2104572T3 (es) N-aminocarbamatos afines a la fisostigmina, un procedimiento para su preparacion y su uso como medicamentos.
PE20080613A1 (es) Derivados de pirazol como agentes antiagregantes plaquetarios y antitromboticos
ES2166379T3 (es) 2-aminotetralinas sustituidas.
AR043959A1 (es) Derivados de indolona-acetamida, procesos para prepararlos, composiciones farmaceuticas que los contienen y su uso como productos farmaceuticos
AR032466A1 (es) Ciclilamina sulfonamidas, utilizacion de las mismas para la manufactura de un medicamento y composiciones farmaceuticas utiles como agonistas de los receptores beta-3 adrenergicos
ECSP066415A (es) 2-carbonilamino-6-piperidinaminopiridinas sustituidas y 1-carbonilamino-3-piperidinaminobenzenos sustituidos como 5-ht1f agonistas
PE20071092A1 (es) Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas

Legal Events

Date Code Title Description
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载